Empagliflozin May be a Game Changer in Managing Pulmonary Embolism: A Case Report
Abstract
Pulmonary Embolism (PE) tolls heavy casualty on human lives because it is often misdiagnosed, and patients have limited access to quality care in resource constraint settings. It usually propagates from deep vein thrombosis of lower limbs. A Bangladeshi old lady suddenly developed symptoms on 19 March 2023. She had predisposing conditions like Type-2 Diabetes mellitus, hypertension and knee replacement surgery that made her bedridden for several years. Finding all the available parameters suggestive of PE, she received standard care but failed to have complete remission. When Empagliflozin was added to her treatment plan, she responded very well and got full recovery off her illness. This is the take away of the story.
How strong is the evidence?
Evidence Hub reads this as a case report, done in people. Its evidence level is 5 of 5 (Very low · case / narrative / animal / in vitro / in silico). Case reports, narrative reviews, and animal, cell or computer-model studies give the weakest evidence for human health.
Read the paper
Related studies
- Strategy for Mitigating DKA Risk in Patients with Type 1 Diabetes on Adjunctive Treatment with SGLT Inhibitors: A STICH Protocol
- Glucoraphanin: a broccoli sprout extract that ameliorates obesity-induced inflammation and insulin resistance
- SGLT2 Inhibitors in Heart Failure: Targeted Metabolomics and Energetic Metabolism
- Mechanisms of blood pressure reduction with sodium-glucose co-transporter 2 (SGLT2) inhibitors
- Sodium-glucose cotransporter inhibitors: beyond glycaemic control
- Decoding the effects of SGLT2 inhibitors on cardiac arrhythmias in heart failure
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.